Intervention Review

You have free access to this content

Insulin and oral agents for managing cystic fibrosis-related diabetes

  1. Gary M Onady1,*,
  2. Adrienne Stolfi2

Editorial Group: Cochrane Cystic Fibrosis and Genetic Disorders Group

Published Online: 26 JUL 2013

Assessed as up-to-date: 22 JUL 2013

DOI: 10.1002/14651858.CD004730.pub3


How to Cite

Onady GM, Stolfi A. Insulin and oral agents for managing cystic fibrosis-related diabetes. Cochrane Database of Systematic Reviews 2013, Issue 7. Art. No.: CD004730. DOI: 10.1002/14651858.CD004730.pub3.

Author Information

  1. 1

    Wright State University, Boonshoft School of Medicine, Dayton, Ohio, USA

  2. 2

    Children's Medical Center, Department of Pediatrics, Dayton, Ohio, USA

*Gary M Onady, Boonshoft School of Medicine, Wright State University, Room 105, Medical Sciences Building, 3640 Colonel Glenn Highway, Dayton, Ohio, OH 45435, USA. gmonady@gmail.com.

Publication History

  1. Publication Status: New search for studies and content updated (conclusions changed)
  2. Published Online: 26 JUL 2013

SEARCH

[Analysis 1.1]
Analysis 1.1. Comparison 1 Insulin versus placebo, Outcome 1 Change in FEV1 (% predicted).
[Analysis 1.2]
Analysis 1.2. Comparison 1 Insulin versus placebo, Outcome 2 Change in FVC (% predicted).
[Analysis 1.3]
Analysis 1.3. Comparison 1 Insulin versus placebo, Outcome 3 Change in BMI.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Insulin versus placebo, Outcome 4 Hypoglycemia.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Repaglinide versus placebo, Outcome 1 Change in FEV1 (% predicted).
[Analysis 2.2]
Analysis 2.2. Comparison 2 Repaglinide versus placebo, Outcome 2 Change in FVC (% predicted).
[Analysis 2.3]
Analysis 2.3. Comparison 2 Repaglinide versus placebo, Outcome 3 Change in BMI.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Repaglinide versus placebo, Outcome 4 Hypoglycemia.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Insulin versus repaglinide, Outcome 1 Change in FEV1 (% predicted).
[Analysis 3.2]
Analysis 3.2. Comparison 3 Insulin versus repaglinide, Outcome 2 Change in FVC (% predicted).
[Analysis 3.3]
Analysis 3.3. Comparison 3 Insulin versus repaglinide, Outcome 3 Change in BMI.
[Analysis 3.4]
Analysis 3.4. Comparison 3 Insulin versus repaglinide, Outcome 4 Hypoglycemia.
[Analysis 4.1]
Analysis 4.1. Comparison 4 NPH insulin versus glargine, Outcome 1 Glucose levels (mg/dl).
[Analysis 4.2]
Analysis 4.2. Comparison 4 NPH insulin versus glargine, Outcome 2 Change in weight (kg).
[Analysis 4.3]
Analysis 4.3. Comparison 4 NPH insulin versus glargine, Outcome 3 Fat mass by DEXA (kg).
[Analysis 4.4]
Analysis 4.4. Comparison 4 NPH insulin versus glargine, Outcome 4 Lean mass by DEXA (kg).
[Analysis 4.5]
Analysis 4.5. Comparison 4 NPH insulin versus glargine, Outcome 5 Hypoglycemic events per participant.